Biomarkers in fibromyalgia: a review

Camillo Giacomelli*
Francesca Sernissi*
Alessandra Rossi
Stefano Bombardieri
Laura Bazzichi

Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

*These authors contributed equally to the manuscript

Abstract: Fibromyalgia is a common syndrome diagnosed by clinical criteria. The main symptom of fibromyalgia is pain, but patients frequently also complain about other nonspecific symptoms, such as headache, sleep disturbance, mood disorder, and cognitive impairment. In the light of the multifactorial origin of the disease and of the lack of objective diagnostic findings, several attempts have been made to find a reliable biomarker. For this reason, over the years, a number of patients and various biological samples have been studied, using many different approaches and techniques. Despite this, none of these studies has been able to find the proper biomarker. The aim of this review is to provide a critical overview of the current environment characterizing the search for fibromyalgia biomarkers.

Keywords: genetics, proteomics, oxidative stress, fibromyalgia

Introduction

Fibromyalgia (FM) is a common syndrome that affects mainly women, with a worldwide prevalence of 2.7% and a male:female ratio of 1:3. According to the recent American College of Rheumatology criteria, FM is a nonautoimmune rheumatic disease characterized by widespread pain and a plethora of nonspecific symptoms, such as cognitive impairment, headache, sleep disturbance, and mood disorder. These criteria focus on pain and related symptoms, and overlap with the first classification criteria (1990), which defined FM as a condition characterized by pain and the presence of multiple tender points. Irrespective of the classification criteria applied, the diagnosis of FM remains basically clinical, and despite the fervent research for FM biomarkers, none of the suggested candidates has yet proven to be convenient, reliable, specific, and sensitive. In fact, in the absence of any classical physiologic alteration, the diagnosis of FM remains clinical, with patients’ reported symptoms (tenderness and pain) used as the gold standard for the diagnosis. Starting from these assumptions, there is a real risk of misdiagnosis, with relevant socioeconomic and treatment consequences.

However, researchers have tried to find a biomarker for this syndrome, for both diagnostic and therapeutical purpose.

Genetics

Since it is known that FM syndrome often occurs in more than one member of a family, it was reasonable to predict that genetic predisposition or other biochemical dysfunctions may be important to the development and/or perpetuation of FM.
Genetic factors are known to influence predisposition to FM, but no specific genes have been definitively involved.\textsuperscript{8}

Many authors have discussed the implication of genetic alterations in FM. In particular, they have focused attention on the alteration of genes involved in nociception, such as the monoamine system, substance P receptors, dopamine transporters, and alpha 1 antitrypsin. The genetic alterations found in FM are showed in Table 1.

### Hematological alterations

#### Autoantibodies

Research on hematologic alterations in FM is desirable. Many studies have been conducted in an effort to find alterations in hematological findings, such as autoantibody levels.

With respect to autoimmunity, one of the investigated antibodies was antipolymer antibody (APA), found in the sera of women with silicone breast implants who presented FM-like symptoms. Wilson et al evaluated APA levels in FM patients and found a higher percentage of APA positivity in the FM group (67%).\textsuperscript{16} However, these results were not confirmed in other studies.\textsuperscript{17} A later study, involving a cohort of 285 FM Italian patients and 100 healthy controls, evaluated APA levels and their correlation with disease severity and cytokine levels.\textsuperscript{18} APA-positivity was detected in only 21.05% of FM patients and 15% of healthy controls, with no significant difference between the two groups. Despite the previous study findings, APA cannot be considered as a FM diagnostic biomarker. However, the presence of APA might be useful in identifying a subgroup of FM patients with more severe symptoms; in fact, in one study, slightly higher APA levels were found in patients with severe disease, and a positive correlation between APA levels and scores on the Fibromyalgia Impact Questionnaire (FIQ) was reported.\textsuperscript{18}

A few other antibodies were also studied in FM. In one study, the levels of antibodies to 5-hydroxytryptamine, gangliosides, and phospholipids were found to be higher in patients with FM and chronic fatigue syndrome (CFS).\textsuperscript{19} In this work the authors reported a statistically significant difference between FM and CFS in terms of serotonin, ganglioside, and phospholipid antibodies. In addition, 49% of FM and 17% of the CFS patients had all three antibodies, and 70% and 55% of patients, respectively had at least two of these antibody types. Based on these findings, the authors proposed the FM syndrome definition of “psychoneuroendocrinological autoimmune diseases”, aimed at emphasizing the etiology of FM.

Moreover, Nishikai et al have proposed anti-68/48 kDa and the anti-45 kDa as possible markers for FM and CFS, specially describing a specific disease subset, which is characterized by a secondary FM form and the copresence

<table>
<thead>
<tr>
<th>Table 1 Genetic alteration in FM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Authors</td>
</tr>
<tr>
<td>-------------</td>
</tr>
<tr>
<td>Caccamo et al</td>
</tr>
<tr>
<td>Smith et al</td>
</tr>
<tr>
<td>Xiao et al</td>
</tr>
<tr>
<td>Potvin et al</td>
</tr>
<tr>
<td>Cohen et al</td>
</tr>
<tr>
<td>Ablin et al</td>
</tr>
<tr>
<td>Tander et al</td>
</tr>
<tr>
<td>Gürsoy et al</td>
</tr>
</tbody>
</table>

**Abbreviations:** S-HT2A, 5-hydroxytryptamine (serotonin) receptor 2A; S-HTTLPR, serotonin-transporter-linked polymorphic region; AHR, sensor aryl hydrocarbon receptor; BDNF, brain-derived neurotrophic factor; CYP, cytochrome; BMI, body mass index; COMT, catechol-O-methyltransferase; CRP, C-reactive protein; DAT, dopamine transporter; FM, fibromyalgia; GABRB3, gamma-aminobutyric acid (GABA) A receptor, beta 3; GBP1, interferon-induced guanylate-binding protein 1; MAO, monoamine oxidase; Met, methionine; SNP, single nucleotide polymorphism; TAAR1, trace amine-associated receptor 1; TACR1, tachykinin receptor 1; Val, valine.
of psychiatric disorders. They found that anti 68/48 kDa protein was present in 15.6% of FM patients and also, that the antibody against 45 kDa protein was present in 37.1% of patients with secondary FM. They also showed that the presence of 68/48 kDa was most frequent in patients with hypersomnia and cognitive impairment. For this reason, these antibodies were not able to support a FM diagnosis; however, they may be useful as markers for a particular subset of FM.

Many patients with FM or other rheumatic conditions, such as rheumatoid arthritis or Sjögren’s syndrome, present with an alteration of thyroid function and have been frequently diagnosed with a thyroid autoimmune disease. In a large cohort of 120 FM patients, Bazzichi et al evaluated the presence of thyroid abnormalities and autoimmunity, observing that FM patients had normal thyroid hormone values but that 41% of the patients had at least one thyroid antibody. The presence of autoimmune thyroiditis was also associated with the typical FM symptoms.

In a later study, Bazzichi et al also observed that the presence of thyroid disease worsened FM symptoms. They evaluated FM comorbidity in patients with Hashimoto’s thyroiditis (HT) with or without subclinical hypothyroidism (SCH), and in patients with SCH alone; as well as the impact of antithyroid autoimmunity and SCH on FM comorbidity. A total of 52 patients, 39 affected by HT with or without SCH and 13 with SCH alone were compared with 37 FM patients and 25 healthy subjects. The researchers found that 31% of HT subjects and none of the SCH patients had FM as a comorbidity. Further, 33.3% of HT patients without SCH and 28.5% of HT patients with SCH had FM comorbidity. Moreover, they observed that the presence of thyroid autoantibodies seemed to worsen the symptoms of FM. The patients with both HT and FM, when compared with patients with SCH, had a significantly higher incidence of positive tender points (100% versus [vs] 23%), diffuse pain (92% vs 8%), fatigue (92% vs 54%), paresthesias (83% vs 31%), nonrestful sleep (75% vs 31%), and affective disorder (58% vs 23%), higher mean FIQ scores (indicating greater impact) (58.70±21.35 vs 17.39±14.48), higher mean visual analog scale (VAS) pain scores (7.50±2.58 vs 1.54±2.54), and higher mean VAS fatigue scores (5.67±2.42 vs 0.38±0.77). They thus supposed a possible relationship between FM and thyroid autoimmunity, suggesting that the presence of thyroid autoimmunity could play a pivotal role in the pathogenesis of FM and that it could help identify patients with a worse prognosis.

Thyroid implication in the etiopathogenesis of FM was also confirmed by other authors who studied the role of thyroperoxidase antibody (TPO Ab). Repeated studies have demonstrated a high prevalence of thyroid autoantibodies in FM patients, but nevertheless, the role of TPO Ab in FM remains unclear. In 2012, Suk et al explored the prevalence of TPO Ab in FM patients with normal thyroid function and studied the potential correlation between autoimmunity and FM clinical profile. They confirmed the observation of a higher frequency of TPO Ab in FM. However, typical findings of FM were not influenced by the presence or absence of TPO Ab. These results confirm that autoimmune thyroiditis may have a role in the development of FM but also, that the presence of TPO Ab itself may not be correlated with the variety and severity of FM symptoms. Similar results were previously reported by Ribeiro and Proietti, who suggested the correlation between FM and thyroid autoimmunity.

Unfortunately, the above mentioned antibodies have no appreciable characteristics of sensitivity and specificity, and moreover, they need to be validated before being considered strong and useful diagnostic biomarkers for FM.

**Oxidative stress**

Several articles reported a linkage between the alteration of oxidative stress response and FM. In Table 2, we report the main articles published in this field. A putative involvement of oxidative stress and FM stems from the observation of clinical response to antioxidative drugs, such as coenzyme Q10 and others vitamins. For instance, few works describe the clinically significant improvement of FM patients treated with oral supplementation of coenzyme Q10, a cofactor known to play an important role in the scavenging of reactive oxygen species. Coenzyme Q10 is a membrane stabilizer and a vital cofactor in the mitochondrial electron transport chain, enabling the generation of adenosine triphosphate (ATP). Cordero et al have published work on the efficacy of coenzyme Q10 in relieving pain and other FM symptoms. Similar results were found by Miyamae et al, who studied the oral supplementation with coenzyme Q10 in ten juvenile FM patients. However, even if oxidative stress plays a pivotal role in FM, there aren’t any specific biomarkers able to evaluate it.

**Cytokines**

Although FM is not an inflammatory disease, many authors have reported the alteration of several cytokines in FM patients. These findings suggest a possible subthreshold inflammation. In a recent meta-analysis, the authors reviewed the literature that investigated cytokines in FM patients. The results,
extrapolated from 1,255 FM patients and 800 healthy subjects, emphasized the role of cytokines, especially for interleukin 6 and interleukin 8. However, the role of cytokines and FM still remains unclear. In Table 3, we summarized the principal findings of studies investigating cytokine levels and FM.

**Other hematological findings**

Over the last 10 years, the literature has reported several other attempts to find reliable biomarkers for FM. For instance, two independent authors found higher serum hyaluronic acid levels in FM patients compared with healthy controls. However, this data has not yet been confirmed, and the significance of this alteration still remains unclear.31,42

Another field of interest is the evaluation of amino acids in the plasma of FM patients. Maes et al found significant lower levels of branched-chain amino acids in the plasma of FM patients, and they speculated that the alteration of branched-chain amino acids could lead to a lack in the supply of energy to the muscle and to altered protein synthesis in the muscles.43 In addition, more recently, an Italian research group found the alteration of several amino acid levels in FM patients.44 In fact, they evaluated the levels of 20 amino acids in plasma from 34 FM patients and found a significantly lower level of taurine, alanine, tyrosine, valine, methionine, phenylalanine, and threonine; these findings could indicate a possible bowel malabsorption of the mentioned amino acids.44

Because of the considerable use of antidepressant drugs, especially serotonin–noradrenaline reuptake inhibitors and selective serotonin reuptake inhibitors, serotonin levels in FM patients cannot be considered as a biomarker. In fact,
one study reported low serum levels of 5-hydroxytryptamine (5-HT) in FM sera with respect to healthy controls and rheumatoid arthritis patients but no differences in serum 5-HT between FM and patients affected by different psychiatric conditions.\(^4\) However, there is also evidence suggesting that FM patients may have alterations – both genetic\(^4\) and functional\(^4\) – in the expression of the 5-HT transporters. Another study found alterations of 5-HT, somatomedin C (a peptide-related to the calcitonin gene), calcitonin, and cholecystokinin, and possible indicators of widespread FM pain;\(^4\) however, these results came from single observations, and therefore validation is needed before conclusions could be drawn. In a recent work published by Ablin et al., leptin levels were studied.\(^4\) The authors don’t observed differences in leptin levels in FM patients compared with the controls.

### Proteomics

In the last few years, proteomic research has been carried out with the main goal of biomarker discovery. In the wake of the interesting results previously reported in rheumatic conditions, such as rheumatoid arthritis, Sjögren’s syndrome, and systemic sclerosis, which are known to frequently overlap with FM syndrome,\(^5\)-\(^7\) an Italian research group also investigated the salivary profile of FM patients.\(^5\) From the analysis of whole saliva from 22 FM patients, the most interesting result was the observation of a significant overexpression of transaldolase (sensitivity of 77.3% and specificity of 84.6%) and phosphoglycerate mutase 1 (PGM-1) in FM patients with respect to healthy controls. Transaldolase is an enzymatic protein involved in the oxidative phase of the pentose phosphate pathway.\(^6\) This enzyme could be overexpressed due to an attempt to limit oxidative damage in tissues; in fact, transaldolase is the rate-limiting enzyme of the nonoxidative part of the pentose phosphate pathway, and as such, it plays a pivotal role in the regulation of the synthesis of nicotinamide adenine dinucleotide phosphate-oxidase (NADPH), as a reductive equivalent.

In addition, researchers found a different expression of several proteins: calgranulin A, calgranulin C, cyclophilin A, profilin 1, Rho guanosine diphosphate (GDP)-dissociation inhibitor 2, proteasome subunit-a-type-2, and haptoglobin-related protein precursor.\(^5\) These proteins have an important role in the immune response, in the cytoskeleton remodeling, and in the inflammatory process, but their role in FM still remains controversial.

### Conclusion

Despite the number of alterations reported in the literature, the diagnosis of FM remains mainly clinical. In fact, the alterations found in FM are aspecific and do not have a high grade of sensitivity and specificity. Considering its multifaceted nature and the plethora of symptoms that characterized this syndrome, it is difficult to think that FM can be explained or diagnosed on the basis of a single biomarker.

For example, thyroid involvement is known to worsen various symptoms in FM patients, especially pain, fatigue, and nonrestful sleep.\(^2\) Also APAs were found to be higher in patients with a severe condition (indicated by increased FIQ scores).\(^7\) Another example of how biomarkers could be used to better assess both syndrome severity and therapy response is represented by plasma coenzyme Q10 levels: it has been shown that where supplementation with coenzyme Q10 obviously led to increased plasmatic levels, at the same time, patients seemed to report an improvement of pain.\(^5\)\(^5\)\(^6\)

However, the results observed in the literature are not consistent and far from allow the use of such biomarkers, in clinical practice, to assess patients’ outcomes in an effective and reliable way. Nonetheless, the genetic studies discussed here, despite being nonhomogeneous in terms of study design and methods, were focused on the same pathway (nociception) and found alterations in biogenic amine expression (5HT, noradrenaline, and dopamine) and metabolism (catechol-O-methyltransferase [COMT] and monoamine oxidase [MAO] enzymes). These alterations, indeed, support the rational on which the more effective FM pharmacological treatments are based: selective serotonin reuptake inhibitors and serotonin–noradrenalin reuptake inhibitors.

Some authors discredit even the existence of FM. Despite this, the observed alterations indicate that large clinical trials, with large cohorts of homogeneous patients stratified according to the different subsets of disease, would be able to identify and validate clusters of biomarkers that could be useful for the assessment and monitoring of specific FM symptoms and disorders (eg, widespread pain, fatigue, mood and sleep disorders, gastrointestinal disorders, etc). From the various papers cited in this review, the main physiologic alterations involved in FM are those related to inflammatory response (cytokines), stress oxidative response, and thyroid function. However, although the molecules found to be implicated in the etiopathogenesis of FM are not constitutive biomarkers, they could play an important role in specific subsets of the disease; if these putative biomarkers were to be successfully validated and meet specific requirements of feasibility and reproducibility, they could eventually be useful for diagnostic and therapeutic purposes.

### Disclosure

The authors report no conflicts of interest in this work.
References